CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of a study in the Journal of Interferon & Cytokine Research by scientists at Alnylam Europe (now Roche Kulmbach), and collaborators, further delineating the mechanisms whereby some siRNAs can trigger immunostimulatory effects in mammalian cells. In addition, this research demonstrates the ability to select or chemically modify siRNAs to avoid such effects.
